Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson, N.; Groot, C.; Jansen, W.J.; Landau, S.M.; Villemagne, V.L.; Engelborghs, S.; Mintun, M.M.; Lleo, A.; Molinuevo, J.L.; Jagust, W.J.; Frisoni, G.B.; Ivanoiu, A.; Chételat, G.; Resende de Oliveira, C.; Rodrigue, K.M.; Kornhuber, J.; Wallin, A.; Klimkowicz-Mrowiec, A.; Kandimalla, R.; Popp, J.; Aalten, P.P.; Aarsland, D.; Alcolea, D.; Almdahl, I.S.; Baldeiras, I.; van Buchem, M.A.; Cavedo, E.; Chen, K.; Cohen, A.D.; Förster, S.; Fortea, J.; Frederiksen, K.S.; Freund-Levi, Y.; Gill, K.D.; Gkatzima, O.; Grimmer, T.; Hampel, H.; Herukka, S.K.; Johannsen, P.; van Laere, K.; de Leon, M.J.; Maier, W.; Marcusson, J.; Meulenbroek, O.; Møllergård, H.M.; Morris, J.C.; Mroczko, B.; Nordlund, A.; Prabhakar, S.; Peters, O.; Rami, L.; Rodríguez-Rodríguez, E.; Roe, C.M.; Rüther, E.; Santana, I.; Schröder, J.; Seo, S.W.; Soininen, H.; Spiru, L.; Stomrud, E.; Struyfs, H.; Teunissen, C.E.; Verhey, FRJ; Vos, SJB; van Waalwijk van Doorn, LJC; Waldemar, G.; Wallin, Å.K.; Wiltfang, J.; Vandenberghe, R.; Brooks, D.J.; Fladby, T.; Rowe, C.C.; Drzezga, A.; Verbeek, M.M.; Sarazin, M.; Wolk, D.A.; Fleisher, A.S.; Klunk, W.E.; Na, D.L.; Sánchez-Juan, P.; Lee, D.Y.; Nordberg, A.; Tsolaki, M.; Camus, V.; Rinne, J.O.; Fagan, A.M.; Zetterberg, H.; Blennow, K.; Rabinovici, G.D.; Hansson, O.; van Berckel, BNM; van der Flier, W.M.; Scheltens, P.; Visser, P.J.; Ossenkoppele, R.

doi:10.1016/j.jalz.2018.02.009

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Détails

Demande d'une copie

ID Serval

serval:BIB_2BF0DD8008FD

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Périodique

Alzheimer's & dementia

Auteur⸱e⸱s

Mattsson N., Groot C., Jansen W.J., Landau S.M., Villemagne V.L., Engelborghs S., Mintun M.M., Lleo A., Molinuevo J.L., Jagust W.J., Frisoni G.B., Ivanoiu A., Chételat G., Resende de Oliveira C., Rodrigue K.M., Kornhuber J., Wallin A., Klimkowicz-Mrowiec A., Kandimalla R., Popp J., Aalten P.P., Aarsland D., Alcolea D., Almdahl I.S., Baldeiras I., van Buchem M.A., Cavedo E., Chen K., Cohen A.D., Förster S., Fortea J., Frederiksen K.S., Freund-Levi Y., Gill K.D., Gkatzima O., Grimmer T., Hampel H., Herukka S.K., Johannsen P., van Laere K., de Leon M.J., Maier W., Marcusson J., Meulenbroek O., Møllergård H.M., Morris J.C., Mroczko B., Nordlund A., Prabhakar S., Peters O., Rami L., Rodríguez-Rodríguez E., Roe C.M., Rüther E., Santana I., Schröder J., Seo S.W., Soininen H., Spiru L., Stomrud E., Struyfs H., Teunissen C.E., Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G., Wallin Å.K., Wiltfang J., Vandenberghe R., Brooks D.J., Fladby T., Rowe C.C., Drzezga A., Verbeek M.M., Sarazin M., Wolk D.A., Fleisher A.S., Klunk W.E., Na D.L., Sánchez-Juan P., Lee D.Y., Nordberg A., Tsolaki M., Camus V., Rinne J.O., Fagan A.M., Zetterberg H., Blennow K., Rabinovici G.D., Hansson O., van Berckel BNM, van der Flier W.M., Scheltens P., Visser P.J., Ossenkoppele R.

ISSN

1552-5279 (Electronic)

ISSN-L

1552-5260

Statut éditorial

Publié

Date de publication

07/2018

Peer-reviewed

Oui

Volume

Numéro

Pages

913-924

Langue

anglais

Notes

Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Résumé

Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology.
We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location.
The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education.
The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.

Mots-clé

Aged, Alleles, Alzheimer Disease/metabolism, Amyloid beta-Peptides/metabolism, Apolipoprotein E4/genetics, Biomarkers/cerebrospinal fluid, Cognitive Dysfunction/metabolism, Europe, Female, Humans, Male, Positron-Emission Tomography, Prevalence, APOE, Age, Alzheimer's disease, Amyloid, CSF, Education, Geographical location, Mild cognitive impairment, PET, Sex, Subjective cognitive decline

OAI-PMH

oai:serval.unil.ch:BIB_2BF0DD8008FD

DOI

10.1016/j.jalz.2018.02.009

Pubmed

29601787

Web of science

000438783200009

Création de la notice

03/04/2018 14:07

Dernière modification de la notice

20/08/2019 14:11

Données d'usage

SERVAL

serveur académique lausannois

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Détails